| pubmed-article:16015389 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0025914 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0033262 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0439064 | lld:lifeskim |
| pubmed-article:16015389 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:16015389 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16015389 | pubmed:dateCreated | 2005-8-24 | lld:pubmed |
| pubmed-article:16015389 | pubmed:abstractText | Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix metalloproteinases (MMPs) and especially MMP-9 is secreted by MM cells. In this study, we investigated the possibility to exploit MMP-9 activity to activate prodrugs and to target MM cells as a new tumour-specific therapy. Cleavage of the prodrug EV1-FITC by MMP-9 resulted in release of fluorescence which can be used as a measure of prodrug activation. The 5T33MM mouse model was used in this proof-of-principle study. The prodrug was activated in a higher amount by addition to MMP-9-producing 5T33MMvv cells, homogenates from tumour-bearing organs (BM, spleen) and isolated 5T33MM-diseased BM and spleen cells compared to non-MMP-9-producing 5T33MMvt cells and homogenates/cells from non-tumour-bearing organs/mice, as measured by fluorescence release. This fluorescence release could be inhibited by the MMP-2/MMP-9-specific inhibitor, CTT. Activation of the prodrug in the 5T33MM spleen and BM homogenates was confirmed by chromatography. EV1-fluorescein isothiocyanate injection into 5T33MM-diseased animals resulted in a higher fluorescence release by the isolated BM and spleen cells compared to injection into healthy animals. In conclusion, MMP-9 activity can be used to activate prodrugs that target MM. | lld:pubmed |
| pubmed-article:16015389 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16015389 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16015389 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16015389 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16015389 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16015389 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16015389 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16015389 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16015389 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16015389 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:YoungLL | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:VanderkerkenK... | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:Van CampBB | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:Van RietII | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:Di SalvoAA | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:16015389 | pubmed:author | pubmed-author:MincherDD | lld:pubmed |
| pubmed-article:16015389 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16015389 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:16015389 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16015389 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16015389 | pubmed:pagination | 1628-33 | lld:pubmed |
| pubmed-article:16015389 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:meshHeading | pubmed-meshheading:16015389... | lld:pubmed |
| pubmed-article:16015389 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16015389 | pubmed:articleTitle | Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. | lld:pubmed |
| pubmed-article:16015389 | pubmed:affiliation | Department of Haematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium. | lld:pubmed |
| pubmed-article:16015389 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16015389 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16015389 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16015389 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16015389 | lld:pubmed |
